Stem-Cells
TREASURE — Allogeneic Stem Cell Therapy for Acute Ischemic Stroke
A multicenter double-blind phase 2/3 RCT in Japan found that allogeneic MultiStem cell therapy within 18–36 hours of acute ischemic stroke was safe but did not improve excellent-outcome rates at 90 days versus placebo, with exploratory subgroup signals in younger patients.